{"commentary":{"count":10,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":5,"podcast":3,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03834961\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03834961","nct_id":"NCT03834961","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03834961. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive larotrectinib PO or by NG or G-tube BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity, or complete surgical resection of tumor.","label":"Treatment (larotrectinib)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-07-25","type":"ESTIMATED"},"conditions":["Central Nervous System Neoplasm","Infantile Fibrosarcoma","Recurrent Acute Leukemia","Refractory Acute Leukemia","Solid Neoplasm"],"enrollment":{"count":33,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Larotrectinib Sulfate","type":"DRUG"}],"last_update":"2025-12-02","lead_sponsor":"Children's Oncology Group","official_title":"Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2024-09-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) of Children With Infantile Fibrosarcoma (IFS) Treated With Neoadjuvant Larotrectinib Prior to Local Control","timeFrame":"Up to 5 years"}],"references":[{"citation":"Laetsch TW, Voss S, Ludwig K, Hall D, Barkauskas DA, DuBois SG, Ronan J, Rudzinski ER, Memken A, Robinson K, Sorger J, Reid JM, Bhatla T, Crompton BD, Church AJ, Fox E, Weigel BJ. Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children's Oncology Group ADVL1823). J Clin Oncol. 2025 Apr;43(10):1188-1197. doi: 10.1200/JCO-24-01854. Epub 2024 Dec 9.","pmid":"39652801","type":"DERIVED"}],"start_date":{"date":"2019-10-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia","url":"https://clinicaltrials.gov/study/NCT03834961"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03834961"}